CAS 76461-17-1

Somatostatin-25

Description:

Somatostatin-25 is a peptide hormone that plays a crucial role in the regulation of various physiological processes, particularly in the endocrine system. It is a truncated form of somatostatin, consisting of 25 amino acids, and is primarily involved in inhibiting the secretion of several other hormones, including growth hormone and insulin. This regulatory function makes it significant in controlling growth, metabolism, and digestive processes. Somatostatin-25 is produced in various tissues, including the hypothalamus and gastrointestinal tract, and it acts through specific receptors to exert its effects. The substance is characterized by its relatively short half-life in circulation, necessitating careful consideration in therapeutic applications. It is often studied for its potential in treating conditions such as acromegaly, neuroendocrine tumors, and other disorders related to hormone dysregulation. As a peptide, it is sensitive to enzymatic degradation, which influences its stability and bioavailability in clinical settings. Overall, Somatostatin-25 is a vital component in the complex interplay of hormonal regulation within the body.

Formula: C₁₂₇H₁₁N₃₇O₃₄S₃

Synonyms:

• H-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH (Disulfide bond)
• Somatostatin (4-28)

Somatostatin-25

CAS: 76461-17-1

Somatostatin: a brain/pancreas hormone binding receptors, with anxiolytic, antiepileptic, and appetite-suppressing effects.

Formula: C₁₂₇H₁₉₁N₃₇O₃₄S₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 2876.3

Ref: TM-TP1810

Somatostatin-25

CAS: 76461-17-1

Somatostatin-25 H-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-(disulfide bond) is a synthetic somatostatin analog that is conjugated to a linker that allows it to be administered intravenously. Somatostatin inhibits the release of growth hormone and insulin from the anterior pituitary gland, and also inhibits the release of other hormones such as glucagon and thyrotropin. Somatostatin has been shown to be effective in treating kidney disease, a condition characterized by increased levels of creatinine and blood urea nitrogen. This drug has been shown to be reversible with the removal of its linker. Somatostatin binds to receptors on pancreatic cells, inhibiting the secretion of digestive enzymes into the gastrointestinal tract. It also blocks insulin release from pancreatic beta cells, which may

Formula: C₁₂₇H₁₉₁N₃₇O₃₄S₃

Purity: Min. 95%

Molecular weight: 2,876.3 g/mol

Ref: 3D-FS110441